Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Palomares Cabeza V, Kummer LYL, Wieske L, Hagen RR, Duurland M, Konijn VAL, van Dam KPJ, Stalman EW, van de Sandt CE, Boekel L, Verstegen NJM, Steenhuis M, Rispens T, Tas SW, Wolbink G, Killestein J, Kuijpers TW, van Ham SM, Eftimov F, Brinke AT, van Kempen ZLE; Target-to-B! (T2B!) SARS-CoV-2 study group.
Palomares Cabeza V, et al. Among authors: van ham sm, van dam kpj, van kempen zle, van de sandt ce.
Neurol Neuroimmunol Neuroinflamm. 2022 May 6;9(4):e1178. doi: 10.1212/NXI.0000000000001178. Print 2022 Jul.
Neurol Neuroimmunol Neuroinflamm. 2022.
PMID: 35523569
Free PMC article.